National Conference on the Consequences of Sodium Valproate (Epilim)

For patients & families, healthcare professionals and policy makers Organised by the Health Service Executive, Epilepsy Ireland, OACS Ireland, Trinity College Dublin and the FACS Forum

Friday March 22nd 2019 – 9.30am – 5pm


More Info:

Stanley Quek Theatre
Biomedical Sciences Institute | Trinity College Dublin
152-160 Pearse Street | Dublin 2

Sodium Valproate (Epilim) is a medication used to treat epilepsy and bipolar disorder. The European Medicines Agency has restricted its use in women due to the increased risk of disabilities in children exposed to Valproate in the womb (Foetal Valproate Syndrome).

This conference will address the key issues today facing families, healthcare professionals, and policy makers in:

  • The pharmacology of sodium valproate
  • Sodium valproate: Who knew what and when?
  • Reducing the risks associated with sodium valproate
  • Diagnosing and managing foetal valproate syndrome
  • Living with foetal valproate syndrome and the consequences of sodium valproate
  • The Irish Health Service’s response to the valproate problem

Speakers include:

  • Dr Colm Henry, HSE Chief Clinical Officer
  • Karen Keely, Chairperson, OACS Ireland
  • Dr Jeff Aronson, Clinical Pharmacologist, Centre for Evidence-Based Medicine, Oxford
  • Prof. Carl Heneghan, Director of the Centre for Evidence-Based Medicine, Oxford
  • Prof. Amanda Wood, Professor of Developmental Neuropsychology, Aston University, Birmingham
  • Dr Peter Turnpenny, Clinical Geneticist, Royal Devon & Exeter Hospital, UK
  • Prof. Andrew Green, Consultant Clinical Geneticist, Our Lady’s Children’s Hospital, Crumlin
  • Families affected by Foetal Valproate Syndrome
  • Members of the HSE’s Valproate Response project team

For further information, please contact:

Sabrina Doyle, HSE: 01 6352508 |

Do you have questions about National Conference on the Consequences of Sodium Valproate (Epilim): 50 years on? 

Contact Epilepsy Ireland